GSK drug flops in leukemia PhIII; Prosecutors want tough Martoma sentence on insider trading;

@FierceBiotech: ICYMI Friday: Another Pfizer bid for AstraZeneca? Investors weigh in. Report | Follow @FierceBiotech

@JohnCFierce: So here's Jeff Stein's new company, Cidara--why all the hush-hush? Release | Follow @JohnCFierce

@DamianFierce: Fun with the U.K. takeover code: $ABBV's $46B bid is blocking $SHPG from shopping for itself. More | Follow @DamianFierce

@EmilyMFierce: Will Europe map the human brain faster than the U.S. can? More from Bloomberg | Follow @EmilyMFierce

> GlaxoSmithKline ($GSK) and its partner Genmab say that ofatumumab (Arzerra) failed a late-stage study for chronic lymphocytic leukemia. Investigators compared the drug against doctor's choice of drugs. Report

U.S. prosecutors are seeking a tough sentence against Mathew Martoma, the former SAC trader recently convicted of insider trading, saying the court's probation department had erred on the side of leniency when it suggested an 8-year prison sentence. Story

Merck ($MRK) says that its drug Emend proved effective in treating pediatric patients, preventing chemo-induced nausea and vomiting in a patient group ranging from 6 months to 17 years old. The drug is approved for adults. Release

Medical Device News

@FierceMedDev: ICYMI: Will Medtronic deal with Covidien benefit smaller players?  exec says yes. Article | Follow @FierceMedDev

@StacyALawrence: ICYMI: FDA clears first robotic exoskeleton for spinal cord injury patients. More | Follow @StacyALawrence

@VarunSaxena2: ICYM last week's feature: Top 10 Med Tech R&D Budgets. Special Report | Follow @VarunSaxena2

@MichaelGFierce: Intersect ENT files for $80M IPO to support steroid-delivering sinus implants. FierceDrugDelivery story | Follow @MichaelGFierce

@EmilyWFierce:  OKs first wearable motorized device that helps people with spinal cord injuries walk, More from the NYT | Follow @EmilyWFierce

> Study: One-third of knee replacements are inappropriate. Article

> Device for 'smart' kegel exercises to debut soon. More

> Researchers develop a durable hydrogel for use with implantable devices. Story

Pharma News

@FiercePharma: Top-read on FP this weekend: Sanofi's Lantus empire imperiled as EU recommends Lilly, Boehringer biosimilar. Article | Follow @FiercePharma

@TracyStaton: Here's @JohnCFierce's take on the Vertex VX-809/Kalydeco PhIII, including interview with CEO Jeff Leiden. Story | Follow @TracyStaton

@EricPFierce: This Indian pharma exec understands how to attain quality production & that many of his compatriots do not. ICYMI from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: ICYMI: Vertex could snag 250 more Kalydeco patients with EMA nod. Item | Follow @CarlyHFierce

> Wanted: Marketing strategy for MannKind's long-time-coming inhaled insulin. More

> Sex, bribes and videotape: Clandestine video of GSK exec adds to China scandal. Report

> Shire CEO's buyout plans thwarted when AbbVie came calling. Article

CRO News

> Recipharm and CTC unite for early-stage trials. Item

> Evotec pockets a payment in its Boehringer partnership. News

> ClinicalRM teams up with an Ohio network for clinical trials. More

> Bristol-Myers enlists Duke's CRO to help it share trial data. Report

> Parexel expects to hit the $2B mark in fiscal 2015. Article

> Covance is creating an OkCupid for molecules. Story

Biotech IT News

> Survey: Firms prioritizing data security over business-boosting analysis. Story

> U.K. scales back plans for patient database as docs back major revision. Report

> NIH aiming to lower IT barriers to 3D printing in drug research. More

> Experts warn FDA Twitter guidance will silence social conversation. Item

> Bristol-Myers strikes deal with Duke to open up trial data. Story

> Europe's brain project plans grant incentives to encourage data sharing. Article

Suggested Articles

Back in 2016, Pfizer signed up with CRO Icon to help it, alongside other CROs PPD and Parexel, run its vast trial network.

French biopharma Servier has bought up Danish cancer biotech Symphogen as it looks to bolster its immuno-oncology pipeline.

Cancer biotech Zentalis Pharmaceuticals priced its IPO at $165 million, eclipsing the $100 million goal it laid out in early March.